secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2024-03-01T23:59:59+00:00
Accession:  0001104659-24-029969
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex prices upsized $400M common stock offering at $47/share, net proceeds ~$376M
--------------------------------------------------------------------------------

- Priced public offering of 8,520,000 shares at $47.00 per share; upsized from initial $250M to $400M.
- Net proceeds expected ~$376.2M after underwriting discounts and expenses.
- Underwriters granted 30-day option to purchase up to an additional 1,278,000 shares.
- Proceeds to fund clinical/preclinical development of barzolvolimab, bispecific antibody platform, and pipeline.
- Offering expected to close on or about March 5, 2024, subject to customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000110465924029969/0001104659-24-029969-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000110465924029969/tm247553d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-029969

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer